Далбаванцин в терапии инфекций кожи и мягких тканей | КМАХ

Далбаванцин в терапии инфекций кожи и мягких тканей

Клиническая Микробиология и Антимикробная Химиотерапия. 2018; 20(4):320-340

​ Никулин А.А., Хачатрян Н.Н.
10.36488/cmac.2018.4.320-340
далбаванцин MRSA инфекции кожи и мягких тканей
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2018; 20(4):320-340

Аннотация

Далбаванцин — полусинтетический липогликопептидный антибиотик, предназначенный для терапии ИКМТ, вызванных грамположительными возбудителями, в том числе метициллино­резистентными S. aureus. Препарат характеризуется длительным периодом полувыведения и высокой биодоступностью, что позволяет назначать его 1 раз в неделю, а также низкими показателями МПК и высоким профилем безопасности. В обзоре представлены данные по in vitro, in vivo и клиническим исследованиям, а также перспективные показания к применению далбаванцина.

Никулин Анатолий Александрович

НИИ антимикробной химиотерапии ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России, Смоленск, Россия

Хачатрян Н.Н.

ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия

  • 1. Esposito S., Noviello S., Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29(2):109­115.
  • 2. Linder K.E., Nicolau D.P., Nailor M.D. Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. Hosp Pract (1995). 2017;45(1):9­15.
  • 3. Olaniyi R., Pozzi C., Grimaldi L., Bagnoli F. Staphylococcus aureus­Associated Skin and Soft Tissue Infections: Anatomical Localization, Epidemiology, Therapy and Potential Prophylaxis. Curr Top Microbiol Immunol. 2017;409:199­227.
  • 4. Posnett J., Gottrup F., Lundgren H., Saal G. The resource impact of wounds on health­care providers in Europe. J Wound Care. 2009;18(4):154­161.
  • 5. Itani K.M., Merchant S., Lin S.J., et al. Outcomes and management costs in patients hospitalized for skin and skin­structure infections. Am J Infect Control. 2011;39(1):42­49.
  • 6. Edelsberg J., Taneja C., Zervos M., et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15(9):1516­1518.
  • 7. Suaya J.A., Mera R.M., Cassidy A., et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis. 2014;14:296.
  • 8. Skin and skin­structure surgical infections. Russian National Recommendations. Savelyev V.S., Ed. Moscow, 200
  • 9. Russian. (Хирургические инфекции кожи и мягких тканей. Российские на­циональные рекомендации. Под ред. В.С. Савельева. Москва, 2009). 9. Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point­prevalence survey of health care­associated infections. N Engl J Med. 2014;370(13):1198­1208.
  • 10. Lautz T.B., Raval M.V., Barsness K.A. Increasing national burden of hospitalizations for skin and soft tissue infections in children. J Pediatr Surg. 2011;46(10):1935­1941.
  • 11. Eagye K.J., Kim A., Laohavaleeson S., Kuti J.L., Nicolau D.P. Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt). 2009;10(4):323­331.
  • 12. Hersh A.L., Chambers H.F., Maselli J.H., Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft­tissue infections. Arch Intern Med. 2008;168(14):1585­1591.
  • 13. Bassetti M., Baguneid M., Bouza E., et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin­resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20 Suppl 4:3­18.
  • 14. Dekhnich A.V., Nikulin A.A., Ryabkova E.L. et al. Epidemiology of resistance of S. aureus strains, selected from ICU patients in Russian hospitals: multicenter study results. Klinicheskaja mimikrobiologija i antimikrobnaja himioterapija. 2008;10(4):333­44. Russian. (Дехнич А.В., Никулин А.А., Рябкова Е.Л., et al. Эпидемиология рези­стентности штаммов S. aureus, выделенных от пациентов в ОРИТ российских стационаров: результаты многоцентрового исследо­вания. Клиническая микробиология и антимикробная химиотера­пия. 2008;10(4):333­344).
  • 15. Romanov A.V., Dekhnich A.V., Sukhorukova M.V., et al. Antimicrobial resistance of nosocomial Staphylococcus aureus isolates in Russia: results of multicenter epidemiological study «MARATHON» 2013­2014. Klinicheskaja mimikrobiologija i antimikrobnaja himioterapija. 2017;19(1):57­62. Russian. (Романов А.В., Дехнич А.В., Сухору­кова М.В., et al. Антибиотикорезистентность нозокомиальных штаммов Staphylococcus aureus в стационарах России: результаты многоцентрового эпидемиологического исследования «Мара­фон» 2013­2014. Клиническая микробиология и антимикробная химиотерапия. 2017;19(1):57­62).
  • 16. Ki V., Rotstein C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19(2):173­184.
  • 17. Kozlov R.S. Krechikova O.I., Ivanchik N.V., et al. Etiology of Nosocomial Bacterial Infections in Russia. Rosnet Study Group. Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25­28; Washington, DC, USA.572.
  • 18. Corey G.R., Stryjewski M.E. New rules for clinical trials of patients with acute bacterial skin and skin­structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis. 2011;52 Suppl 7:S469­476.
  • 19. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147­159.
  • 20. US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. October, 2013.
  • 21. Hachatryan N.N., Dizengof I.M., Smirnov G.G., et al. Features of antibacterial therapy for surgical infections of the skin and soft tissues. Consilium Medicum Hirurgija. 2011;1:34­7. Russian. (Хачатрян Н.Н. Дизенгоф И.М., Смирнов Г.Г., et al. Особенности антибакте­риальной терапии хирургических инфекций кожи и мягких тканей. Consilium Medicum Хирургия (Прил). 2011;1:34­37.).
  • 22. Surgical infections of the skin and soft tissues. Russian national recommendations. 2nd revised and enlarged edition. Moscow, 2015. Russian. (Хирургические инфекции кожи и мягких тканей. Россий­ские национальные рекомендации. 2­е переработанное и допол­ненное издание. Москва, 2015.).
  • 23. Moran G.J., Abrahamian F.M., Lovecchio F., Talan D.A. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44(6):e397­412.
  • 24. Garau J., Ostermann H., Medina J., et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010­2011): assessment of clinical practice patterns and real­life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377­385.
  • 25. Zhanel G.G., Calic D., Schweizer F., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859­886.
  • 26. Guskey M.T., Tsuji B.T. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30(1):80­94.
  • 27. Bailey J., Summers K.M. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2008;65(7):599­610.
  • 28. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin­resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18­55.
  • 29. Moet G.J., Jones R.N., Biedenbach D.J., Stilwell M.G., Fritsche T.R. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998­2004). Diagn Microbiol Infect Dis. 2007;57(1):7­13.
  • 30. Abbas M., Paul M., Huttner A.. New and improved? A review of novel antibiotics for Gram­positive bacteria. Clin Microbiol Infect. 2017;23(10):697­703.
  • 31. Arias C.A., Murray B.E. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266­278.
  • 32. Bal A.M., David M.Z., Garau J., et al. Future trends in the treatment of methicillin­resistant Staphylococcus aureus (MRSA) infection: An in­depth review of newer antibiotics active against an enduring pathogen. J Glob Antimicrob Resist. 2017;10:295­303.
  • 33. Richter S.S., Diekema D.J., Heilmann K.P., et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13­valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484­6489.
  • 34. Chambers H.F., Deleo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629­641.
  • 35. Chua K., Laurent F., Coombs G., Grayson M.L., Howden B.P. Antimicrobial resistance: Not community­associated methicillin­resistant Staphylococcus aureus (CA­MRSA)! A clinician’s guide to community MRSA ­ its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52(1):99­114.
  • 36. David M.Z, Daum R.S. Community­associated methicillin­resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616­687.
  • 37. DeLeo F.R., Otto M., Kreiswirth B.N., Chambers H.F. Community­associated meticillin­resistant Staphylococcus aureus. Lancet. 2010;375(9725):1557­1568.
  • 38. Tong S.Y., Davis J.S., Eichenberger E., Holland T.L., Fowler V.G. Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603­661.
  • 39. Bowen A.C., Tong S.Y., Andrews R.M., et al. Short­course oral co­trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open­label, randomised, controlled, non­inferiority trial. Lancet. 2014;384(9960):2132­2140.
  • 40. Miller L.G., Daum R.S., Chambers H.F. Antibacterial Treatment for Uncomplicated Skin Infections. N Engl J Med. 2015;372(25):2460.
  • 41. Miller L.G., Daum R.S., Creech C.B., et al. Clindamycin versus trimethoprim­sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015;372(12):1093­1103.
  • 42. Nguyen H.M., Graber C.J. Limitations of antibiotic options for invasive infections caused by methicillin­resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother. 2010;65(1):24­36.
  • 43. Gould I.M., David M.Z., Esposito S., et al. New insights into meticillin­resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39(2):96­104.
  • 44. Dryden M.S. Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection? Curr Opin Infect Dis. 2015;28(2):117­124.
  • 45. Rodvold K.A., McConeghy K.W. Methicillin­resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58 Suppl 1:S20­27.
  • 46. Castanheira M., Jones R.N., Sader H.S. Update of the in vitro activity of daptomycin tested against 6710 Gram­positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis. 2008;61(2):235­239.
  • 47. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin­Intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(3):1079­1082.
  • 48. Patel J.B., Jevitt L.A., Hageman J., McDonald L.C., Tenover F.C. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 2006;42(11):1652­1653.
  • 49. Sader H.S., Streit J.M., Fritsche T.R., Jones R.N. Antimicrobial susceptibility of gram­positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002­2004). Clin Microbiol Infect. 2006;12(9):844­852.
  • 50. Sakoulas G., Alder J., Thauvin­Eliopoulos C., Moellering R.C. Jr., Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50(4):1581­1585.
  • 51. van Hal S.J., Paterson D.L., Gosbell I.B. Emergence of daptomycin resistance following vancomycin­unresponsive Staphylococcus aureusbacteraemia in a daptomycin­naive patient ­ a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30(5):603­610.
  • 52. van Harten R.M., Willems R.J.L., Martin N.I., Hendrickx A.P.A. Multidrug­Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies? Trends Microbiol. 2017;25(6):467­479.
  • 53. Gu B., Kelesidis T., Tsiodras S., Hindler J., Humphries R.M. The emerging problem of linezolid­resistant Staphylococcus. J Antimicrob Chemother. 2013;68(1):4­11.
  • 54. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. 2013. Available at www.fda.gov/Drugs/DrugSafety/ucm369580.htm.
  • 55. Prasad P., Sun J., Danner R.L., Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699­1709.
  • 56. Yahav D., Lador A., Paul M., Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta­analysis. J Antimicrob Chemother. 2011;66(9):1963­1971.
  • 57. Tasina E., Haidich A.B., Kokkali S., Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta­analysis. Lancet Infect Dis. 2011;11(11):834­844.
  • 58. Cai Y., Wang R., Liang B., Bai N., Liu Y. Systematic review and meta­analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55(3):1162­1172.
  • 59. Butler M.S., Hansford K.A., Blaskovich M.A., Halai R., Cooper M.A. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014;67(9):631­644.
  • 60. Leadbetter M.R., Adams S.M., Bazzini B., et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD­6424). J Antibiot (Tokyo). 2004;57(5):326­336.
  • 61. European Medicines Agency. Xydalba 500 mg powder for concentrate for solution for infusion: summary of product chracteristics 2016. Available from: www.ema.europa.eu.
  • 62. Durata Therapeutics US Ltd. Dalvance (dalbavancin) for injection, for intravenous use: US prescribing information. Available from: www.dalvance.com.
  • 63. Malabarba A., Goldstein B.P.. Origin, structure, and activity in vitroand in vivo of dalbavancin. J Antimicrob Chemother. 2005;55 Suppl 2:ii15­20.
  • 64. Billeter M., Zervos M.J., Chen A.Y., Dalovisio J.R., Kurukularatne C. Dalbavancin: a novel once­weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46(4):577­583.
  • 65. Kim A., Kuti J.L., Nicolau D.P. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007;16(5):717­733.
  • 66. Sosio M., Stinchi S., Beltrametti F., Lazzarini A., Donadio S. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species. Chem Biol. 2003;10(6):541­549.
  • 67. Zhanel G.G., Trapp S., Gin A.S., et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram­positive infections. Expert Rev Anti Infect Ther. 2008;6(1):67­81.
  • 68. Lin G., Credito K., Ednie L.M., Appelbaum P.C. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005;49(2):770­772.
  • 69. Lopez S., Hackbarth C., Romano G., et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005;55 Suppl 2:ii21­24.
  • 70. Leighton A., Gottlieb A.B., Dorr M.B., et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940­945.
  • 71. Chong Y.P., Park S.J., Kim H.S., et al. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin­resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis. 2012;73(3):264­266.
  • 72. Citron D.M., Tyrrell K.L., Goldstein E.J. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcusspecies cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis. 2014;79(4):438­440.
  • 73. Jones R.N., Flamm R.K., Sader H.S. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis. 2013;76(1):122­123.
  • 74. Jones R.N., Sader H.S., Flamm R.K. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304­307.
  • 75. Jones R.N., Biedenbach D.J., Johnson D.M., Pfaller M.A. In vitroevaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother. 2001;13(3):244­254.
  • 76. Streit J.M., Fritsche T.R., Sader H.S., Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48(2):137­143.
  • 77. Jones R.N., Fritsche T.R., Sader H.S., Goldstein B.P. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005;17(6):593­600.
  • 78. Gales A.C., Sader H.S., Jones R.N. Antimicrobial activity of dalbavancin tested against Gram­positive clinical isolates from Latin American medical centres. Clin Microbiol Infect. 2005;11(2):95­100.
  • 79. Streit J.M., Sader H.S., Fritsche T.R., Jones RN. Dalbavancin activity against selected populations of antimicrobial­resistant Gram­positive pathogens. Diagn Microbiol Infect Dis. 2005;53(4):307­310.
  • 80. Jones R.N., Sader H.S., Fritsche T.R., Stilwell M.G. Dalbavancin activity tested against rarely isolated Gram­positive organism species from Europe. Int J Antimicrob Agents. 2007;29 Suppl (S2):195­196.
  • 81. Biedenbach D.J., Bell J.M., Sader H.S., Turnidge J.D., Jones R.N. Activities of dalbavancin against a worldwide collection of 81,673 gram­positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260­1263.
  • 82. Biedenbach D.J., Jones R.N. Multicenter evaluation of the in vitroactivity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagn Microbiol Infect Dis. 2009;64(2):177­184.
  • 83. Jones R.N., Farrell D.J., Moet G.J., Sader H.S. Potency of Dalbavancin Tested Against 37,258 Gram­positive Cutaneous Pathogens from USA Medical Centers (2006­2009). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, 17­20 September 2011. Abstr. E­1323.
  • 84. Karlowsky J.A., Adam H.J., Poutanen S.M., et al. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007­2009 study. Diagn Microbiol Infect Dis. 2011;69(3):342­347.
  • 85. McCurdy S.P., Jones R.N., Mendes R.E., Puttagunta S., Dunne M.W. In Vitro Activity of Dalbavancin against Drug­Resistant Staphylococcus aureus Isolates from a Global Surveillance Program. Antimicrob Agents Chemother. 2015;59(8):5007­5009.
  • 86. Mendes R.E., Castanheira M., Farrell D.J., et al. Update on dalbavancin activity tested against Gram­positive clinical isolates responsible for documented skin and skin­structure infections in US and European hospitals (2011­13). J Antimicrob Chemother. 2016;71(1):276­278.
  • 87. Pfaller M.A., Mendes R.E., Duncan L.R., Flamm R.K., Sader H.S. Activity of dalbavancin and comparator agents against Gram­positive cocci from clinical infections in the USA and Europe 2015­16. J Antimicrob Chemother. 2018;73(10):2748­2756.
  • 88. Biedenbach D.J., Ross J.E., Fritsche T.R., Sader H.S., Jones R.N. Activity of dalbavancin tested against Staphylococcus spp. and beta­hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol. 2007;45(3):998­1004.
  • 89. Naimi T.S., LeDell K.H., Como­Sabetti K., et al. Comparison of community­ and health care­associated methicillin­resistant Staphylococcus aureus infection. JAMA. 2003;290(22):2976­2984.
  • 90. Huang V., Cheung C.M., Kaatz G.W., Rybak M.J. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community­associated and multidrug­resistant hospital­associated meticillin­resistant Staphylococcus aureus. Int J Antimicrob Agents. 2010;35(1):25­29.
  • 91. Lefort A., Pavie J., Garry L., Chau F., Fantin B. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother. 2004;48(3):1061­1064.
  • 92. Bozdogan B., Esel D., Whitener C., Browne F.A., Appelbaum P.C. Antibacterial susceptibility of a vancomycin­resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother. 2003;52(5):864­868.
  • 93. Jones R.N., Stilwell M.G. Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains). Diagn Microbiol Infect Dis. 2013;76(2):239­240.
  • 94. Candiani G., Abbondi M., Borgonovi M., Romano G., Parenti F. In­vitro and in­vivo antibacterial activity of BI 397, a new semi­synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999;44(2):179­192.
  • 95. Lin G., Smith K., Ednie L.M., Appelbaum P.C. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob Agents Chemother. 2005;49(12):5182­5184.
  • 96. Dunne M., Boucher H., Wilcox M., Puttagunta S., Talbot G. Microbiologic analysis of target pathogens identified in the dalbavancin DISCOVER program. Presented at IDWeek 2013, October 2­6, 2013, San Francisco, California, USA. Abstr. 1338 plus poster.
  • 97. Jones R.N., Farrell D.J., Flamm R.K., et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82(1):73­77.
  • 98. Goldstein E.J., Citron D.M., Merriam C.V., et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram­positive species and corynebacteria. Antimicrob Agents Chemother. 2003;47(6):1968­1971.
  • 99. Goldstein E.J., Citron D.M., Warren Y.A., et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram­positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother. 2006;50(8):2875­2879.
  • 100. Heine H.S., Purcell B.K., Bassett J., Miller L., Goldstein B.P. Activity of dalbavancin against Bacillus anthracisin vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010;54(3):991­996.
  • 101. Rolston K.V., Wang W., Nesher L., Shelburne S.A., Prince R.A. In vitroactivity of dalbavancin and five comparator agents against common and uncommon Gram­positive organisms isolated from cancer patients. J Antibiot (Tokyo). 2016;69(5):381­387.
  • 102. Andes D., Craig W.A. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633­1642
  • 103. Jabes D., Candiani G., Romano G., et al. Efficacy of dalbavancin against methicillin­resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother. 2004;48(4):1118­1123.
  • 104. Johnson D.M., Fritsche T.R., Sader H.S., Jones R.N. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006;27(6):557­560.
  • 105. Koeth L.M. D­FJ., Dunne M., et al. Dalbavancin and azithromycin synergy/antagonism study by checkerboard MIC. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Washington DC, 5­9 September 2014. Abstr. D­877.
  • 106. Goldstein B.P., Draghi D.C., Sheehan D.J., Hogan P., Sahm D.F. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother. 2007;51(4):1150­1154.
  • 107. Leuthner K.D., Buechler K.A., Kogan D., Saguros A., Lee H.S. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931­940.
  • 108. Scoble P.J., Owens R.C., Jr., Puttagunta S., Yen M., Dunne M.W. Pharmacokinetics, Safety, and Tolerability of a Single 500­mg or 1000­mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clin Drug Investig. 2015;35(12):785­793.
  • 109. Buckwalter M., Dowell J.A. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45(11):1279­1287.
  • 110. Marbury T., Dowell J.A., Seltzer E., Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49(4):465­476.
  • 111. Cavaleri M., Riva S., Valagussa A., et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005;55 Suppl 2:ii31­35.
  • 112. Chen A.Y., Zervos M.J., Vazquez J.A. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007;61(5):853­863.
  • 113. Nicolau D.P., Sun H.K., Seltzer E., Buckwalter M., Dowell J.A. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60(3):681­684.
  • 114. Dorr M.B., Jabes D., Cavaleri M., et al. Human pharmacokinetics and rationale for once­weekly dosing of dalbavancin, a semi­synthetic glycopeptide. J Antimicrob Chemother. 2005;55 Suppl 2:ii25­30.
  • 115. Seltzer E., Dorr M.B., Goldstein B.P., et al. Once­weekly dalbavancin versus standard­of­care antimicrobial regimens for treatment of skin and soft­tissue infections. Clin Infect Dis. 2003;37(10):1298­1303.
  • 116. Dunne M.W., Puttagunta S., Sprenger C.R., et al. Extended­duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849­1855.
  • 117. Cada D.J., Ingram K., Baker D.E. Dalbavancin. Hosp Pharm. 2014;49(9):851­861.
  • 118. Bradley J.S., Puttagunta S., Rubino C.M., et al. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12­17 Years of Age. Pediatr Infect Dis J. 2015;34(7):748­752.
  • 119. Gonzalez D., Bradley J.S., Blumer J., et al. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Pediatr Infect Dis J. 2017;36(7):645­653.
  • 120. Dowell J.A., Goldstein B.P., Buckwalter M., Stogniew M., Damle B. Pharmacokinetic­pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol. 2008;48(9):1063­1068.
  • 121. Bowker K.E., Noel A.R., MacGowan A.P. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother. 2006;58(4):802­805.
  • 122. Bhavnani S.M., Hammel J.P., Rubino C.M., et al. Pharmacokinetic­Pharmacodynamic (PK­PD) Analyses for the efficacy of dalbavancin using phase 3 data from patients with acute bacterial skin and skin structure infections. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, 5­9 September 2014. Abstr. E­1323.
  • 123. Raad I., Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter­related bloodstream infection caused by gram­positive pathogens. Clin Infect Dis. 2005;40(3):374­380.
  • 124. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double­blind comparison of once­weekly dalbavancin versus twice­daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407­1415.
  • 125. Boucher H.W., Wilcox M., Talbot G.H., et al. Once­weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169­2179.
  • 126. Dunne M.W., Puttagunta S., Giordano P., et al. A Randomized Clinical Trial of Single­Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin Infect Dis. 2016;62(5):545­551.
  • 127. Agarwal R., Bartsch S.M., Kelly B.J., et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta­analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361­368.
  • 128. Guest J.F., Esteban J., Manganelli A.G., et al. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta­analysis. PLoS One. 2017;12(11):e0187792.
  • 129. Kussmann M., Obermueller M., Berndl F., et al. Dalbavancin for treatment of implant­related methicillin­resistant Staphylococcus aureusosteomyelitis in an experimental rat model. Sci Rep. 2018;8(1):9661.
  • 130. Darouiche R.O., Mansouri M.D. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect. 2005;50(3):206­209.
  • 131. Barnea Y., Lerner A., Aizic A., et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J Antimicrob Chemother. 2016;71(2):460­463.
  • 132. Diaz­Ruiz C., Alonso B., Cercenado E., et al. Can dalbavancin be used as a catheter lock solution? J Med Microbiol. 2018;67:936­944.
  • 133. Bouza E., Valerio M., Soriano A., et al. Dalbavancin in the treatment of different gram­positive infections: a real­life experience. Int J Antimicrob Agents. 2018;51(4):571­577.
  • 134. Barber K.E., Tirmizi A., Finley R., Stover K.R. Dalbavancin Use for the Treatment of Methicillin­resistant Staphylococcus aureus Pneumonia. J Pharmacol Pharmacother. 2017;8(2):77­79.
  • 135. Almangour T.A., Fletcher V., Alessa M., Alhifany A.A., Tabb D. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin­Resistant Staphylococcus Aureus: A Case Report. Am J Case Rep. 2017;18:1315­1319.
  • 136. Woelber E., Schrick E.J., Gessner B.D., Evans H.L. Proportion of Surgical Site Infections Occurring after Hospital Discharge: A Systematic Review. Surg Infect (Larchmt). 2016;17(5):510­519.
  • 137. Galluzzo M., D’Adamio S., Bianchi L., Talamonti M. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. Expert Opin Drug Metab Toxicol. 2018;14(2):197­206.
  • 138. Dunne M.W., Talbot G.H., Boucher H.W., Wilcox M., Puttagunta S. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Saf. 2016;39(2):147­157.
  • 139. Decousser J.W., Bourgeois­Nicolaos N., Doucet­Populaire F. Dalbavancin, a long­acting lipoglycopeptide for the treatment of multidrug­resistant Gram­positive bacteria. Expert Rev Anti Infect Ther. 2007;5(4):557­571.
  • 140. Barriere S., Genter F., Spencer E., et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004;44(7):689­695.
  • 141. Dunne M.W., Zhou M., Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin­structure infections. Int J Antimicrob Agents. 2015;45(4):393­398.
  • 142. Trevino J., Bayon C., Arda A., et al. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Chemistry (Easton). 2014;20(24):7363­7372.
  • 143. Puttagunta S., Boucher H., Talbot G., et al. Dalbavancin vs vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies. IDWeek 2014. Philadelphia, 8­12 October 2014. Abstr. 266.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились